4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Casopitant: a novel NK 1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer. The knowledge of the pathogenesis and neuropharmacology of CINV has expanded enormously over the last decades, the most significant discoveries being the role of 5-hydroxytryptamine (5-HT) 3- and neurokinin (NK) 1 receptors in the emetic reflex arch. This has led to the development of two new classes of antiemetics acting as highly selective antagonists at one of these receptors. These drugs have had a huge impact in the protection from chemotherapy-induced vomiting, whereas the effect on nausea seems to be limited. The first NK 1 receptor antagonist, aprepitant, became clinically available in 2003, and casopitant, the second in this class of antiemetics, has now completed phase III trials. This review delineates the properties and clinical use of casopitant in the prevention of CINV.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2009
          2009
          20 May 2009
          : 5
          : 375-384
          Affiliations
          Odense University Hospital, Department of Oncology, Odense, Denmark
          Author notes
          Correspondence: Christina Ruhlmann, Odense University Hospital, Department of Oncology, Sdr. Boulevard 29, DK-5000, Odense C, Denmark, Tel +45 6541 3834, Email christina.ruhlmann@ 123456ouh.regionsyddanmark.dk
          Article
          tcrm-5-375
          2697542
          19536319
          © 2009 Ruhlmann and Herrstedt, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          chemotherapy, emesis, nk1 receptor antagonist, casopitant, gw679769

          Comments

          Comment on this article